|Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents|
USPTO Class 530 | Browse by Industry: Previous - Next | All
Recent | 14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereofBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 07/10/2014 > 11 patent applications in 9 patent subcategories.
20140194593 - Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use: The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between... Agent: Yeda Research And Development Co., Ltd.
20140194594 - Synthetic peptides and peptide mimetics: The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics.... Agent: University Of Louisville Research Foundation, Inc.
20140194595 - Method and composition for crystallizing g protein-coupled receptors: Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and... Agent:
20140194598 - B7-related nucleic acids and polypeptides useful for immunomodulation: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated... Agent: Bristol-myers Squibb Company
20140194596 - Dual specificity antibody fusions: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.... Agent: Ucb Pharma S.a.
20140194597 - Modified chimeric polypeptides with improved pharmacokinetic properties: The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.... Agent: Regeneron Pharmaceuticals, Inc.
20140194599 - Anti-human interleukin-20 antibodies: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods... Agent: Novo Nordisk A/s
20140194600 - Use of anti-factor xi antibodies for prevention of thrombus formation: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI... Agent: Prothix B.v.
20140194601 - Antibody drug conjugates (adc) that bind to 161p2f10b proteins: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.... Agent: Agensys, Inc.
20140194602 - Metamaterial optical elements self-assembled on protein scaffolds: A genetically modified cowpea mosaic virus (CPMV) protein capsid serves as a scaffold for metal nanoparticles, preferably gold nanospheres, of 15 nm to 35 nm, creating plasmonic nanoclusters. The self-assembled nanoclusters gave rise to a 10-fold surface-averaged enhancement of the local electromagnetic field. Other viral capsids or virus-like proteins may... Agent: The Government Of The United States Of America, As Represented By The Secretary Of The Navy
20140194603 - Method for the production of lignin-containing precursor fibres and also carbon fibres: The invention relates to a method for the production of a precursor for the production of carbon- and activated carbon fibres according to the wet- or air-gap spinning method, in which a solution of lignin and a fibre-forming polymer in a suitable solvent is extruded through the holes of a... Agent: Stora Enso Oyj07/03/2014 > 20 patent applications in 15 patent subcategories.
20140187741 - Means and methods for mediating protein interference: The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein... Agent: Vib Vzw
20140187742 - Methods for purifying pertussis toxin and peptides useful therefor: The present invention relates to reagents and methods for purifying pertussis toxin (PT).... Agent:
20140187744 - Bilirubin excretion enhancer: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one... Agent: Nipro Corporation
20140187743 - Surface-active collagen membrane by peptide: The present invention provides a collagen membrane having surface activity by a fusion peptide bound to the surface thereof. When the collagen membrane is transplanted in vivo, the retention time of the fusion peptide in a local region can increase, and the fusion peptide can promote the cell migration, proliferation... Agent: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.
20140187745 - Method for preparing bivalirudin: A method for preparing bivalirudin. The method includes preparing a bivalirudin resin by a solid phase synthesis, performing acidolysis of the bivalirudin resin to obtain crude bivalirudin, and purifying the crude bivalirudin to obtain purified bivalirudin. The solid phase synthesis method includes successively coupling Fmoc-protected amino acids corresponding to a... Agent: Chengdu Shengnuo Tech Co., Ltd.
20140187746 - Precipatable peptides: The invention is directed to a Ca2+ precipatable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising Ca2+ precipatable tags and cassettes.... Agent: The Trustees Of Columbia University In The City Of New York
20140187747 - Discordant helix stabilization for prevention of amyloid formation: The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the α-helix of a... Agent: Alphabeta Ab
20140187748 - Mirac proteins: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.... Agent: Bioatla, LLC
20140187750 - Methods for selecting protease resistant polypeptides: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing... Agent: Glaxo Group Limited
20140187749 - Single unit chromatography antibody purification: The present invention relates to a method for the purification of antibodies from a protein mixture produced in a bioreactor, at least comprising the steps of intermediate purification and polishing, wherein the intermediate and polishing step comprises in-line anion exchange chromatography (AEX) treatment and mixed mode chromatography (MiMo) treatment in... Agent: DsmIPAssets B.v.
20140187754 - Anti-fgfr3 antibodies and methods using same: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.
20140187752 - Antigenic compositions and use of same in the targeted delivery of nucleic acids: Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized, for example by receptor-mediated endocytosis. The chimeric... Agent: Akshaya Bio Inc.
20140187753 - Hetero-dimeric immunoglobulins: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.... Agent: Glenmark Pharmaceuticals S.a.
20140187751 - Purification of fusion proteins: The invention relates generally to methods for purifying a Fc-fusion protein produced in a eukaryotic expression system. More specifically, the invention provides a robust and scalable downstream purification process suitable for use in manufacturing TNFR:Fc for human administration which comprises an optimized Protein A affinity chromatography step and two ion... Agent: Merck
20140187755 - Clostridial neurotoxins with altered persistency: (c) at least one further LC domain or fragment thereof of the neurotoxic component of a clostridial toxin wherein the first and the at least one further LC domain may be the same or different from each other, and wherein each of said fragments of said first and of said... Agent: Merz Pharma Gmbh & Co. Kgaa
20140187756 - Methods of preparing antibody-active agent conjugates: The invention provides methods for preparing an antibody-active agent conjugate. The conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and... Agent: Legochem Biosciences, Inc.
20140187757 - Methods and compositions: e
20140187758 - Methods for purifying insect membrane-bound receptor proteins from recombinant production hosts: The invention is drawn to a method for purifying membrane-bound proteins expressed in recombinant insect cells using N-laurosarcosine. The invention is particularly suited for expressing cadherin-type receptors cloned from Ostrinia nubilalis, European Corn Borer, and expressed in Sf9 insect cells. The method is optionally adapted for use with 6-his tag... Agent: Dow Agrosciences LLC
20140187759 - Biorefining processes and apparatus for separating cellulose hemicellulose, and lignin from biomass: The disclosed invention is a modification of the AVAP® technology, employing CO2 (or derivatives thereof) rather than SO2 in the cooking liquor. In some variations, the invention provides a process for fractionating cellulosic biomass into cellulose, hemicellulose, and lignin, comprising: fractionating the feedstock in the presence of a solvent for... Agent: Api Intellectual Property Holdings, LLC
20140187760 - Lignin precipitation methods: A method of separating lignin from black liquor from a pulp mill by adjusting the pH of the black liquor is provided. Various additional steps can be used to further process the separated lignin, including washing, drying, and/or comminuting. In certain embodiments, solvents and byproducts are recycled so as to... Agent: Weyerhaeuser Nr Company06/26/2014 > 11 patent applications in 10 patent subcategories.
20140179896 - Inhibitors of type 2 vascular endothelial growth factor receptors: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.... Agent: Bristol-myers Squibb Company
20140179897 - Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline: The present invention relates to the crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline. The present invention also relates to processes for preparing dolamethylleuine and dolaphenvaline. The present invention further relates to computer readable medium with crystal structural data and/or information stored thereon.... Agent:
20140179899 - Double-acylated glp-1 derivatives: e
20140179898 - Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent: A modified protein of an extracellular domain of protein A, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein A, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data... Agent: Nat'l Institute Of Advanced Industrial Science And Technology
20140179900 - Treatment of atherosclerosis with cholesterol ester transport protein mimotopes: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.... Agent: Affiris Ag
20140179901 - Peptide conjugates and fluorescence detection methods for intracellular caspase assay: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and... Agent: Applied Biosystems, LLC
20140179902 - Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or... Agent: Molecular Insight Pharmaceuticals, Inc.
20140179903 - High affinity human antibodies to human protease-activated receptor 2: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders... Agent: Regeneron Pharmaceuticals, Inc.
20140179904 - Protein purification using hcic and ion exchange chromatography: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.... Agent: Medarex, L.L.C.
20140179905 - Methods and compositions for targeting polyubiquitin: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.... Agent: Genentech, Inc.
20140179906 - Conjugation methods: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without... Agent: Immunogen, Inc.06/19/2014 > 9 patent applications in 7 patent subcategories.
20140171618 - Method for preparing multiple antigen glycopeptide carbohydrate conjugates: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.... Agent: Institut Pasteur
20140171619 - Peptide-crosslinked bioactive polymeric materials: A method for creating a peptide crosslinked bioactive polymeric material includes reacting a hydroxy-functionalized small molecule with a amino acid to form an amino acid functionalized monomer, reacting the amino acid functionalized monomer with a urea bond former to form a amino acid-based poly(ester urea), and reacting the amino acid-based... Agent: The University Of Akron
20140171620 - Ciliary neurotrophic factor variants: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose... Agent: Christian-albrechts-universitat Zu Kiel
20140171622 - Fusion proteins forming trimers: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are... Agent: Apogenix Gmbh
20140171621 - Galectin-immunoglobulin chimeric molecules: Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.... Agent: The Brigham And Women's Hospital, Inc.
20140171623 - Modulation of antibody effector function by hinge domain engineering: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc... Agent: Medimmune, LLC
20140171624 - Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy: Described are compounds capable of modulating (a) the biological activity of ADP-dependent glucokinase (ADPGK) and/or glycerol-3-phosphate dehydrogenase (GPD2) or (b) the expression of the gene encoding ADPGK or GPD2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system,... Agent: Deutsches Krebsforschungszentrum Stiftung Des Ö Ffentlichen Rechtes
20140171625 - Cardiotrophin related molecules for enhanced therapeutics: The invention provides novel polypeptides having at least one biological activity of cardiotrophin and improved biologic drug-like properties, and polynucleotides encoding the polypeptides of the invention. The polypeptides of the invention can be used therapeutically, such as, for example, in methods of tissue regeneration.... Agent: Fate Therapeutics, Inc.
20140171626 - Protein purification: Processes for the purification of NY-ESO-1 related polypeptides, as well as polypeptides produced by these processes are provided herein; a composition comprising pure and stable NY-ESO-1 is also provided.... Agent: Glaxosmithkline LLCPrevious industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series
RSS FEED for 20140710:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.
Results in 0.37167 seconds